• News
  • Medical

BioTheranostics gets OK to perform Breast Cancer Index testing

The New York State Department of Health has approved the use of San Diego-based bioTheranostics Inc.’s Breast Cancer Index, a molecular test that determines risk of early and late recurrence and benefit from extended endocrine therapy in patients with early stage, estrogen receptor-positive breast cancer.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!